Gedeon Richter UK acquires neuropsychiatry product Reagila from Recordati in the UK

Gedeon Richter UK Ltd (“Gedeon Richter UK”) today announced that full marketing and distribution rights to the neuropsychiatry treatment Reagila® (cariprazine), acquired from Recordati Pharmaceuticals Ltd (“Recordati”), have been transferred to the affiliate organisation. Under the terms of the transfer, Gedeon Richter UK picks up the rights for UK promotion of cariprazine, while remaining the Marketing Authorisation holder in the UK.

Cariprazine, a product of Gedeon Richter Plc’s (“Richter”) R&D, is licensed for the treatment of schizophrenia in adult patients. The acquisition signifies Gedeon Richter UK’s intent to help as many patients as possible nationwide and represents a strong strategic fit, with products for conditions affecting the central nervous system an important and growing part of Richter’s portfolio range. The UK joins a group of countries (dominantly in Central and Eastern Europe) where Richter has been marketing cariprazine through its direct affiliates. Richter’s network of partner companies commercialises the drug in other countries around the world.

“We are proud of Richter’s heritage in neuropsychiatry and the pivotal role we played in the development of cariprazine, which was first discovered by Richter scientists in the early 2000s,” said Remigijus Narauskas, Managing Director, Gedeon Richter UK and Ireland. “A strategic decision has been made to bring UK commercialisation of cariprazine to Gedeon Richter UK, and we would like to thank Recordati for its role in leading the marketing and distribution of the drug over the last nine years.”

As part of the transfer, Joe Durante has moved to Gedeon Richter UK, assuming the position of National Neuroscience Advisor in January 2026. He previously held the position of National Neuroscience Advisor at Recordati. 

“Schizophrenia is a chronic and disabling disorder that imposes a significant burden on patients and their loved ones,” said David Jordan, Medical Director, Gedeon Richter UK and Ireland. “We are committed to improving the quality of life for those suffering from this chronic mental health condition and we are pleased to continue providing cariprazine to eligible patients throughout the UK.”

Patients already taking cariprazine in the UK will continue to receive their treatment distributed by Gedeon Richter.

About Reagila® (cariprazine) 
Cariprazine is an antipsychotic medicine licensed for the treatment of schizophrenia in adults. Cariprazine was discovered by Richter, and jointly developed by Allergan (earlier Forest / Actavis) and Richter for the treatment of schizophrenia. Cariprazine received Marketing Authorisation in the EU in July 2017 for the treatment of schizophrenia, and was approved by the MHRA for schizophrenia in September 2018.

About schizophrenia 
Schizophrenia is a long-term mental health condition. Schizophrenia affects around 220,000 people in England and Wales. It is most likely to develop between the ages of 20 and 30 years, though it also develops in younger and older people, and tends to develop later in women compared to men. Symptoms fall into two broad categories: positive symptoms (such as hallucinations, delusions, disorganised thinking) and negative symptoms (such as less emotion, lack of motivation, speaking less and wanting to isolate). 

About Gedeon Richter Plc
Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalisation of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest research and development (R&D) hub. Richter focuses its R&D activities in Neuropsychiatry and Women's Healthcare, and strives to make Biotechnology and General Medicines therapies more accessible. 

About Gedeon Richter UK Ltd
Gedeon Richter has been operating in the UK for over 60 years under the name Medimpex UK. In 2012, Gedeon Richter UK began commercialising Richter’s products with a key focus on women’s health. Since then, the company’s portfolio has grown further to include biosimilars and CNS products. Therapy areas include: hormone replacement therapy; heavy menstrual bleeding and contraception; emergency contraception; fertility; uterine fibroids; endometriosis; osteoporosis and schizophrenia.